Table 1. Patients characteristics.
| Clinical or pathological feature | Total N | Prior oxaliplatin-based chemotherapy | P value | |
|---|---|---|---|---|
| No | Yes | |||
| All cases | 336 | 170 | 166 | |
| Mean age ± SD | 64.5 ± 10.7 | 66.3 ± 10.4 | 62.7 ± 10.7 | 0.0019 |
| Sex | 0.23 | |||
| Male | 217 (65%) | 115 (68%) | 102 (61%) | |
| Female | 119 (35%) | 55 (32%) | 64 (39%) | |
| Number of liver metastasis | 0.0002 | |||
| 1 | 146 (43%) | 91 (53%) | 55 (33%) | |
| 2- | 190 (57%) | 79 (47%) | 111 (67%) | |
| Tumor location | 0.18 | |||
| Proximal colon | 70 (21%) | 41 (24%) | 29 (18%) | |
| Distal colon | 135 (40%) | 70 (41%) | 65 (39%) | |
| Rectum | 131 (39%) | 59 (35%) | 72 (43%) | |
| Tumor differentiation | 0.12 | |||
| Well | 95(28%) | 56 (33%) | 39 (24%) | |
| Moderate | 219 (65%) | 102 (60%) | 117 (70%) | |
| Others | 22 (6.6%) | 12 (7.1%) | 10 (6.0%) | |
| Prior chemotherapy | ||||
| None | 170 (100%) | |||
| mFOLFOX6 | 92 (55%) | |||
| mFOLFOX+bevacizumab | 52 (33%) | |||
| XELOX+bevacizumab | 5 (3.0%) | |||
| XELOX | 3 (1.8%) | |||
| Others | 14 (8.4%) | |||
(%) indicates the proportion of cases with a specific clinical or pathological feature among each group (prior chemotherapy Yes or No)